Brief: Trilink Biotechnologies And Lonza Enter Non-Exclusive License And Supply Agreement For Cleancap MRNA Capping Technology
30/04/2024 12:35
April 30 (Reuters) - Maravai LifeSciences Holdings Inc
MRVI.O :
* TRILINK BIOTECHNOLOGIES® AND LONZA ENTER INTO
NON-EXCLUSIVE
LICENSE AND SUPPLY AGREEMENT FOR CLEANCAP® MRNA CAPPING
TECHNOLOGY
* TRILINK BIOTECHNOLOGIES: TRILINK WILL SUPPLY PATENTED
CLEANCAP
ANALOGS FOR USE IN LONZA'S GLOBAL MRNA DEVELOPMENT AND
MANUFACTURING SERVICES
Source text for Eikon: ID:nBwbgLy66a
Further company coverage: MRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maravai Lifesciences Holdings
See all newsMaravai LifeSciences Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Maravai LifeSciences Q2 revenue beats estimates on strong TriLink demand
Maravai LifeSciences Holdings Inc expected to post a loss of 4 cents a share - Earnings Preview
Maravai LifeSciences Q1 revenue rises on higher CleanCap sales
Brief: Maravai LifeSciences Q1 Revenue USD 65.8 Million Vs. IBES Estimate USD 53 Million